注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户？ 登录
🔥 我们的AI选股策略科技巨头，自五月以来已大涨7.1%。立即领略AI风采，抓住热门股机遇。
领取六折优惠
BlackRock Health Sciences Opportunities Portfolio Investor A Shares (SHSAX)
从投资组合添加/删除
添加至投资组合
- 晨星评级:
- 总资产: 2.9B
BlackRock Health Sciences Opps Inv A
70.83
+0.02
+0.03%
SHSAX概述
本页面提供BlackRock Health Sciences Opportunities Portfolio Investor A Shares的详细介绍，帮助您了解SHSAX的高管、总资产、投资策略和联系方式等信息。
联络信息
高管
| 名称 | 标题 | 任期 | 至 |
|---|---|---|---|
| Xiang Liu | Director | 2020 | now |
| 背景介紹 | Xiang Liu, PhD, Director, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the medical devices & supplies sector. Prior to joining BlackRock in 2008, Mr. Liu was a partner and biotech analyst at Mehta Partners. From 2002 to 2005, he was a Director in the corporate development department at Cubist Pharmaceuticals. Mr. Liu began his investment career in 2000 at the Boston Consulting Group as a Healthcare consultant. Mr. Liu earned a BS degree in Chemistry from the University of Science & Technology, China in 1993, a PhD degree in Chemistry from Yale University in 1997, and a MBA degree in finance, strategy, and accounting from the University of Chicago in 2000. | ||
| Erin Xie | Managing Director | 2003 | now |
| 背景介紹 | Erin Xie, PhD, Managing Director and portfolio manager, is the head of the Health Sciences team, part of BlackRock’s Active Equity Group. She is the lead portfolio manager for the Health Sciences equity portfolios. Ms. Xie's service with the firm dates back to 2001, including her years with State Street Research & Management (SSRM), which merged with BlackRock in 2005. At SSRM, she was a Senior Vice President and portfolio manager responsible for managing the State Street Health Sciences Fund. Prior to joining State Street Research in 2001, Ms. Xie was a research associate with Sanford Bernstein covering the pharmaceutical industry from 1999. From 1994 until 1997, she was a post doctoral research scientist at Columbia University. Ms. Xie earned a BS degree in chemistry from Beijing University in 1988, a PhD degree in Biochemistry from the University of California, Los Angeles, in 1993 and a MBA degree from the Massachusetts Institute of Technology Sloan School of Management in 1999. | ||
| Jeff Lee | - | 2020 | 2023 |
| 背景介紹 | Jeffrey Lee, Director, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the healthcare providers and services sector. Prior to joining BlackRock in 2011, Mr. Lee was a member of the healthcare investment team at Duquesne Capital Management where he covered provider and service companies. From 2006 to 2008, Mr. Lee was an healthcare private equity associate at Altaris Capital Partners where he sourced and analyzed equity transactions for public and private healthcare companies. Prior to 2006, Mr. Lee was an analyst at Citigroup within the healthcare finance and investment banking group where he valued and helped structured financing for managed care providers, hospital companies and other large healthcare systems. Mr. Lee earned a BA degree in economics, cum laude, from Princeton University in 2004. | ||
| Thomas P. Callan | Managing Director | 2005 | 2017 |
| 背景介紹 | Thomas P. Callan, CFA, Managing Director and senior portfolio manager, is head of BlackRock's Global Opportunities equity team. He oversees the team's investment process, leads the team's Investment Strategy Group, and provides portfolio and risk management oversight for all of the team's products. In addition, Mr. Callan is a member of BlackRock's Leadership Committee. Mr. Callan's service with the firm dates back to 1988, including his years with PNC Asset Management Group, which was integrated with BlackRock in 1998. He started as a health care analyst for PNC's mutual fund group and later served as an international equity analyst. Mr. Callan began his investment career at PNC Bank as a personal trust portfolio manager in 1988. Mr. Callan earned a BA degree in economics, with honors, from Boston College in 1981. | ||
| Ajay Mehra | Managing Director | 2003 | 2005 |
| 背景介紹 | Prior to founding Foresight Global Investors, Ajay was a Managing Director and Head of Equities at Salient Partners where he managed their global equity strategy in both SMA and Mutual Fund (SGEIX) format. Prior to Salient, Dr. Mehra served as Managing Director and Head of Manager and Fund Research at UBS. In this role, he was responsible for overseeing the manager search and ongoing due diligence activities for the group. Dr. Mehra was also a Partner and Portfolio Manager at private equity firm Columbus Nova, where he co-managed a global macro fund, did principal investments and managed a long biased global equity fund. Dr. Mehra has also held the positions of Managing Director and Head of Equity Research for State Street Research, where he was the lead portfolio manager for a Health Sciences fund (selected as the Lipper Best Health Sciences Fund 2003 and 2004) and a Large-Cap fund. Prior to joining State Street Research, he was a Senior Vice President and Portfolio Manager for Columbia Management Group. Ajay began his investment career at Morgan Stanley where he was the firm's Consumer Products analyst. Prior to that, he was Assistant Professor of Strategic Management at West Virginia University's College of Business and Economics. Dr. Mehra holds a B.S. and M.B.A. from Panjab University in Chandigarth, India. He also earned a Ph.D. from the University of Massachusetts, where his doctoral dissertation was selected as a finalist for the Best Dissertation award by the Academy of Management and was subsequently published as a book | ||
| Management Team | - | 2003 | 2003 |
| 背景介紹 | Team Managed | ||
| John R. Borzilleri | Portfolio Manager | 1999 | 2003 |
| 背景介紹 | John R. Borzilleri, MD is a general partner and portfolio manager for the GRT Health Care Fund. Dr. Borzilleri has thirteen years of experience in investment management and research. From inception in late 1999 until his departure in June 2003, Dr. Borzilleri was the portfolio manager of the State Street Research and Management Health Sciences Fund. For the three years ending June 2003, the Health Sciences Fund reported annualized returns of +12.89, representing top decile Lipper performance in the health care category. From 1997 until his departure, Dr. Borzilleri was also a senior health care analyst at State Street Research, with broad coverage of the pharmaceutical, biotechnology and medical service sectors. For his last 2 years at State Street Research, Dr. Borzilleri was the health care sector head, with responsibility for managing a team of 3 other analysts. From October 1995 to June 1997, Dr. Borzilleri was the senior pharmaceutical analyst at San Francisco-based Montgomery Securities, with analytic responsibility for large, mid and small capitalization drug companies. From October 1993 to October 1995, Dr. Borzilleri was the senior pharmaceutical and biotechnology analyst at Dean Witter in New York. From August 1991 to October 1993, Dr. Borzilleri was a junior pharmaceutical and biotechnology analyst at Sanford Bernstein. Dr. Borzilleri holds a BS degree in Biology from Brown University (’81), an MD from New York University (’85) and an MBA from Columbia University (’91). Between medical and business school, Dr. Borzilleri spent 5 years in residency training and the practice of medicine. | ||
写出您对于 BlackRock Health Sciences Opportunities Portfolio Investor A Shares 的看法
确定删除此图表？
删除 取消
用新图表更换现在所附的图表？
更换 取消
评论指南
在评论中添加图表
确认屏蔽
确定屏蔽%USER_NAME%？
如果屏蔽，您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人，因此必须等待48小时才能重新屏蔽。
举报该评论
您举报该评论的原因为：
该评论已被标注
谢谢您!
您的举报将会被发送到管理员进行审核